Personal information

No personal information available

Activities

Collapse all

Employment (1)

Helsinki University Hospital: Helsinki, FI

2020-02-01 to present | Clinical researcher / Specialising physician (Oncology) (HUS Comprehensive Cancer Center)
Employment
Source: Self-asserted source
Ilkka Liikanen

Education and qualifications (4)

University of Helsinki: Helsinki, FI

2021-10-14 to present | Associate professor (Docent) in Experimental Oncology
Education
Source: Self-asserted source
Ilkka Liikanen

University of California San Diego: La Jolla, CA, US

2015-06-01 to 2021-04-01 | Postdoctoral fellow (Division of Biological Sciences, UCSD)
Education
Source: Self-asserted source
Ilkka Liikanen

University of Helsinki: Helsinki, FI

2011-06-01 to 2015-04-15 | M.D. Ph.D. (Faculty of Medicine, Doctoral Programme in Biomedicine)
Education
Source: Self-asserted source
Ilkka Liikanen

University of Helsinki: Helsinki, FI

2005-08-15 to 2011-05-31 | M.D. (Faculty of Medicine)
Education
Source: Self-asserted source
Ilkka Liikanen

Works (24)

Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer

Journal for ImmunoTherapy of Cancer
2022-02 | Journal article
DOI: 10.1136/jitc-2021-003490
Contributors: Ilkka Liikanen; Saru Basnet; Dafne C A Quixabeira; Kristian Taipale; Otto Hemminki; Minna Oksanen; Matti Kankainen; Juuso Juhila; Anna Kanerva; Timo Joensuu et al.
Source: check_circle
Crossref

Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells

Journal of Clinical Investigation
2021-04-01 | Journal article
DOI: 10.1172/JCI143729
Contributors: Ilkka Liikanen; Colette Lauhan; Sara Quon; Kyla Omilusik; Anthony T. Phan; Laura Barceló Bartrolí; Amir Ferry; John Goulding; Joyce Chen; James P. Scott-Browne et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy

Molecular Therapy - Oncolytics
2018-06 | Journal article
DOI: 10.1016/j.omto.2018.04.003
Part of ISSN: 2372-7705
Source: Self-asserted source
Ilkka Liikanen

Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients

Oncotarget
2018-01-19 | Journal article
DOI: 10.18632/oncotarget.23967
Part of ISSN: 1949-2553
Source: Self-asserted source
Ilkka Liikanen

Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer

Molecular Cancer Therapeutics
2016-09-01 | Journal article
DOI: 10.1158/1535-7163.mct-15-0819
Part of ISSN: 1535-7163
Part of ISSN: 1538-8514
Source: Self-asserted source
Ilkka Liikanen

Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy

Molecular Therapy
2016-07 | Journal article
DOI: 10.1038/mt.2016.67
Part of ISSN: 1525-0016
Source: Self-asserted source
Ilkka Liikanen

Fate of fenestration in children treated with fontan operation

Catheterization and Cardiovascular Interventions
2016-05 | Journal article
DOI: 10.1002/ccd.26324
Part of ISSN: 1522-1946
Source: Self-asserted source
Ilkka Liikanen

Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer

OncoImmunology
2016-02 | Journal article
DOI: 10.1080/2162402x.2015.1078057
Part of ISSN: 2162-402X
Source: Self-asserted source
Ilkka Liikanen

Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus

Molecular Therapy
2016-01 | Journal article
DOI: 10.1038/mt.2015.143
Part of ISSN: 1525-0016
Source: Self-asserted source
Ilkka Liikanen

Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Resultsin vitro, in rodents and in humans

International Journal of Cancer
2015-10-01 | Journal article
DOI: 10.1002/ijc.29536
Part of ISSN: 0020-7136
Source: Self-asserted source
Ilkka Liikanen

T-cell Subsets in Peripheral Blood and Tumors of Patients Treated With Oncolytic Adenoviruses

Molecular Therapy
2015-05 | Journal article
DOI: 10.1038/mt.2015.17
Part of ISSN: 1525-0016
Source: Self-asserted source
Ilkka Liikanen

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy

OncoImmunology
2015-03-04 | Journal article
DOI: 10.4161/2162402x.2014.989771
Part of ISSN: 2162-402X
Source: Self-asserted source
Ilkka Liikanen

Case–Control Estimation of the Impact of Oncolytic Adenovirus on the Survival of Patients With Refractory Solid Tumors

Molecular Therapy
2015-02 | Journal article
DOI: 10.1038/mt.2014.218
Part of ISSN: 1525-0016
Source: Self-asserted source
Ilkka Liikanen

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy

Oncotarget
2015-02-28 | Journal article
DOI: 10.18632/oncotarget.2901
Part of ISSN: 1949-2553
Source: Self-asserted source
Ilkka Liikanen

Combining Oncolytic Immunotherapy with Conventional Cancer Treatments

2015-02-13 | Dissertation or Thesis
URI: http://urn.fi/URN:ISBN:978-951-51-0577-6
Source: Self-asserted source
Ilkka Liikanen

Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans

International Journal of Cancer
2014-08-01 | Journal article
DOI: 10.1002/ijc.28696
Part of ISSN: 0020-7136
Source: Self-asserted source
Ilkka Liikanen

Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment

Journal of Translational Medicine
2013 | Journal article
DOI: 10.1186/1479-5876-11-193
Part of ISSN: 1479-5876
Source: Self-asserted source
Ilkka Liikanen

Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients

Molecular Therapy
2013-06 | Journal article
DOI: 10.1038/mt.2013.51
Part of ISSN: 1525-0016
Source: Self-asserted source
Ilkka Liikanen

Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus

Clinical Cancer Research
2013-05-15 | Journal article
DOI: 10.1158/1078-0432.ccr-12-2546
Part of ISSN: 1078-0432
Part of ISSN: 1557-3265
Source: Self-asserted source
Ilkka Liikanen

Verapamil Results in Increased Blood Levels of Oncolytic Adenovirus in Treatment of Patients With Advanced Cancer

Molecular Therapy
2012-01 | Journal article
DOI: 10.1038/mt.2011.230
Part of ISSN: 1525-0016
Source: Self-asserted source
Ilkka Liikanen

Induction of Interferon Pathways Mediates In Vivo Resistance to Oncolytic Adenovirus

Molecular Therapy
2011-10 | Journal article
DOI: 10.1038/mt.2011.144
Part of ISSN: 1525-0016
Source: Self-asserted source
Ilkka Liikanen

Adenoviral E4orf3 and E4orf6 Proteins, But Not E1B55K, Increase Killing of Cancer Cells by Radiotherapy in vivo

International Journal of Radiation Oncology*Biology*Physics
2010-11 | Journal article
DOI: 10.1016/j.ijrobp.2010.05.037
Part of ISSN: 0360-3016
Source: Self-asserted source
Ilkka Liikanen

Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1

Clinical Cancer Research
2010-05-01 | Journal article
DOI: 10.1158/1078-0432.ccr-09-2974
Part of ISSN: 1078-0432
Part of ISSN: 1557-3265
Source: Self-asserted source
Ilkka Liikanen

Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures

European Journal of Cancer
2010-02 | Journal article
DOI: 10.1016/j.ejca.2009.11.005
Part of ISSN: 0959-8049
Source: Self-asserted source
Ilkka Liikanen
How many people are using ORCID?